Skip to content

Jason M Tucciarone

3 papers in the library · 9 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

5-HT2A receptor and psychedelics: a trip through the mechanisms of action and therapeutic potential in mental disorders

Translational Psychiatry September 14, 2026 Muhammad Asim, Julia A. Galiza Soares, Jason M Tucciarone

Serotonin (5-hydroxytryptamine; 5-HT) modulates a vast array of brain functions via its diverse receptor subtypes. Among these, the serotonin 5-HT2A receptor (5-HT2AR) has garnered intense recent interest for its pivotal role in mediating the effects of psychedelic compounds. Substantial evidence indicates that psychedelics act as agonists at the 5-HT2AR, triggering profound alterations in...

Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.

American Journal of Psychiatry June 1, 2026 Jason M Tucciarone, Igor D. Bandeira, Christine Blasey et al. 5 citations

Ketamine rapidly reduces suicidal ideation in major depressive disorder (MDD), but its effects are transient. Preclinical and clinical studies suggest that ketamine's antidepressant and antisuicidal effects may be partly mediated by mu-opioid receptor (MOR) modulation. The authors investigated the efficacy and safety of low-dose sublingual buprenorphine, a partial MOR agonist, as a follow-on...

Methodological considerations for interpreting ketamine-naltrexone trials in depression

The International Journal of Neuropsychopharmacology October 1, 2025 Igor D. Bandeira, Luke A. Jelen, Jason M Tucciarone et al. 4 citations

Igor D Bandeira, MD, PhD, Luke A Jelen, MD, PhD, Jason M Tucciarone, MD, PhD, Boris D Heifets, MD, PhD, Carolyn I Rodriguez, MD, PhD, Alan F Schatzberg, MD

DOI: 10.1093/ijnp/pyaf073 (opens in new tab) Full text (opens in new tab) Depression economics Medline Clinical trial Clinical neurology +1